Re: Friedreich’s Ataxia Therapy News - Very interesting
in response to
by
posted on
May 26, 2017 04:01PM
BDAZ, I believe that as long as the RVX-208 label does not claim an effect on patients suffering from FA, there are no problems with the Pfizer patent application (should it be granted). Any MD can prescribe RVX-208 off label to a patient with FA. However, if Resverlogix should claim that there is an effect of RVX-208 on FA, I guess that Resverlogix would have to come to some agreement with Pfizer. Anyway, I think this is very hypothetical.